Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) headquartered in Emeryville, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.adamaspharma.com
Earnings Expectation
Adamas Pharmaceuticals, Inc. is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, ADMS is expected to report 3Q20 loss of $ 0.48 per share from revenue of $ 20.95 million.
For the full year, analysts anticipate top line of $ 76.67 million, while looking forward to loss of $ 1.92 per share bottom line.
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
